Artigo

Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

Autor(es): Harold J. Burstein, MD, PhD1 ; Angela DeMichele, MD2 ; Lesley Fallowfield, DPhil3; Mark R. Somerfield, PhD4 ; and N. Lynn Henry, MD, PhD5 ; for the Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels

ABSTRACT

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better informhealth practitioners and the public on the best available cancer care options. Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

Compartilhar em:

Compartilhar em:

Kit-MKT-Breast-Breaking-NewsAvatar
Breast Breaking News
13/03/2024

Comentários

Deixe um comentário

0

Conteúdos Relacionados

Sem Título

Cardiologia
08/04/2024
Thumb (17)
23:07
SBMN sem fundo

Medicina Nuclear
10/04/2024
Thumb (14)
20:11

Comentários

Deixe um comentário

Carrinho de compras